Cargando…

World Antibody-Drug Conjugate Summit, October 15–16, 2013, San Francisco, CA

The World Antibody-Drug Conjugate (WADC) Summits organized by Hanson Wade are currently the largest meetings fully dedicated to ADCs. The first global ADC Summit was organized in Boston in October 2010. Since 2011, two WADC are held every year in Frankfurt and San Francisco, respectively. The 2013 W...

Descripción completa

Detalles Bibliográficos
Autores principales: Klinguer-Hamour, Christine, Strop, Pavel, Shah, Dhaval K, Ducry, Laurent, Xu, April, Beck, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929441/
https://www.ncbi.nlm.nih.gov/pubmed/24423618
http://dx.doi.org/10.4161/mabs.27437
_version_ 1782304392756592640
author Klinguer-Hamour, Christine
Strop, Pavel
Shah, Dhaval K
Ducry, Laurent
Xu, April
Beck, Alain
author_facet Klinguer-Hamour, Christine
Strop, Pavel
Shah, Dhaval K
Ducry, Laurent
Xu, April
Beck, Alain
author_sort Klinguer-Hamour, Christine
collection PubMed
description The World Antibody-Drug Conjugate (WADC) Summits organized by Hanson Wade are currently the largest meetings fully dedicated to ADCs. The first global ADC Summit was organized in Boston in October 2010. Since 2011, two WADC are held every year in Frankfurt and San Francisco, respectively. The 2013 WADC San Francisco event was structured around plenary sessions with keynote speakers from AbbVie, Agensys, ImmunoGen, Immunomedics, Genentech, Pfizer and Seattle Genetics. Parallel tracks were also organized addressing ADC discovery, development and optimization of chemistry, manufacturing and control (CMC) issues. Discovery and process scientists, regulatory experts (US Food and Drug Administration), academics and clinicians were present, including representatives from biotechnology firms (Concortis, CytomX Therapeutics, Glykos, Evonik, Igenica, Innate Pharma, Mersana Therapeutics, Polytherics, Quanta Biodesign, Redwood Bioscience, Sutro Biopharma, SynAffix), pharmaceutical companies (Amgen, Genmab, Johnson and Johnson, MedImmune, Novartis, Progenics, Takeda) and contract research or manufacturing organizations (Baxter, Bayer, BSP Pharmaceuticals, Fujifilm/Diosynth, Lonza, Pierre Fabre Contract Manufacturing, Piramal, SAFC, SafeBridge).
format Online
Article
Text
id pubmed-3929441
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-39294412014-03-05 World Antibody-Drug Conjugate Summit, October 15–16, 2013, San Francisco, CA Klinguer-Hamour, Christine Strop, Pavel Shah, Dhaval K Ducry, Laurent Xu, April Beck, Alain MAbs Meeting Report The World Antibody-Drug Conjugate (WADC) Summits organized by Hanson Wade are currently the largest meetings fully dedicated to ADCs. The first global ADC Summit was organized in Boston in October 2010. Since 2011, two WADC are held every year in Frankfurt and San Francisco, respectively. The 2013 WADC San Francisco event was structured around plenary sessions with keynote speakers from AbbVie, Agensys, ImmunoGen, Immunomedics, Genentech, Pfizer and Seattle Genetics. Parallel tracks were also organized addressing ADC discovery, development and optimization of chemistry, manufacturing and control (CMC) issues. Discovery and process scientists, regulatory experts (US Food and Drug Administration), academics and clinicians were present, including representatives from biotechnology firms (Concortis, CytomX Therapeutics, Glykos, Evonik, Igenica, Innate Pharma, Mersana Therapeutics, Polytherics, Quanta Biodesign, Redwood Bioscience, Sutro Biopharma, SynAffix), pharmaceutical companies (Amgen, Genmab, Johnson and Johnson, MedImmune, Novartis, Progenics, Takeda) and contract research or manufacturing organizations (Baxter, Bayer, BSP Pharmaceuticals, Fujifilm/Diosynth, Lonza, Pierre Fabre Contract Manufacturing, Piramal, SAFC, SafeBridge). Landes Bioscience 2014-01-01 2013-12-06 /pmc/articles/PMC3929441/ /pubmed/24423618 http://dx.doi.org/10.4161/mabs.27437 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Meeting Report
Klinguer-Hamour, Christine
Strop, Pavel
Shah, Dhaval K
Ducry, Laurent
Xu, April
Beck, Alain
World Antibody-Drug Conjugate Summit, October 15–16, 2013, San Francisco, CA
title World Antibody-Drug Conjugate Summit, October 15–16, 2013, San Francisco, CA
title_full World Antibody-Drug Conjugate Summit, October 15–16, 2013, San Francisco, CA
title_fullStr World Antibody-Drug Conjugate Summit, October 15–16, 2013, San Francisco, CA
title_full_unstemmed World Antibody-Drug Conjugate Summit, October 15–16, 2013, San Francisco, CA
title_short World Antibody-Drug Conjugate Summit, October 15–16, 2013, San Francisco, CA
title_sort world antibody-drug conjugate summit, october 15–16, 2013, san francisco, ca
topic Meeting Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929441/
https://www.ncbi.nlm.nih.gov/pubmed/24423618
http://dx.doi.org/10.4161/mabs.27437
work_keys_str_mv AT klinguerhamourchristine worldantibodydrugconjugatesummitoctober15162013sanfranciscoca
AT stroppavel worldantibodydrugconjugatesummitoctober15162013sanfranciscoca
AT shahdhavalk worldantibodydrugconjugatesummitoctober15162013sanfranciscoca
AT ducrylaurent worldantibodydrugconjugatesummitoctober15162013sanfranciscoca
AT xuapril worldantibodydrugconjugatesummitoctober15162013sanfranciscoca
AT beckalain worldantibodydrugconjugatesummitoctober15162013sanfranciscoca